Turnstone biologics corp. reports fourth quarter and full year 2023 financial results and provides recent business highlights

Lead program, tidal-01, advancing in phase 1 trials with initial clinical data expected in mid-2024 promising preclinical data highlighting turnstone's novel selected til programs for solid tumors presented at sitc 2023 further strengthened scientific advisory board with appointment of internationally recognized cancer immunotherapy expert, dr. jeffrey s. weber san diego, march 21, 2024 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided recent business highlights.
TSBX Ratings Summary
TSBX Quant Ranking